国际标准期刊号: 1522-4821

国际紧急心理健康和人类复原力杂志

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 引用因子
  • 西马戈
  • 大英图书馆
  • 斯科普斯
  • 参考搜索
  • 普布隆斯
  • 大学教育资助委员会
  • 欧洲酒吧
  • 出版医学
  • ICMJE
分享此页面

抽象的

Use of Human Embryonic Stem Cells in the Treatment of Parkinsons Disease: A Case Report

Geeta Shroff and Petra Hopf-Seidel

Parkinson’s disease (PD), a progressive disorder of the central nervous system, affects every 1 in 100 persons, aged around 70 in Europe. PD is characterized by abnormalities affecting both the motor system and the non-motor systems that include tremor, gait disorder, bradykinesia, depression, cognitive impairments, dysautonomia and sleep disturbances. Both surgical and drug treatments are available for the treatment of PD, but none has been able to halt the progression of the degenerative disease. We present the case of 65-year old male patient with PD who was treated with human embryonic stem cells (hESCs). The patient showed significant improvement in his health following the treatment; such as reduction in tremors, bradykinesia, muscle rigidity, pain and stiffness in the neck, shoulder and low back and improvement in the range of movements of the neck. The patient was able to balance himself while walking, had reduction in numbness in his left hand and both of his legs. He was able to speak louder and had improved writing skills. No adverse event or teratoma formation was observed. hESC therapy in our study showed beneficial effects in the patient with PD, but future clinical trials are needed to gather more evidence to support our findings.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。